• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Biological activity of Ab is a critical component
3. B cell-directed immunotherapies
4. Antigen expression during B cell development
5. B lymphocyte targets for immunotherapy
6. CD20 immunotherapy for lymphoma
7. CD20-directed immunotherapies (1)
8. CD20-directed immunotherapies (2)
9. CD20 immunotherapy for lymphoma - rituximab
10. Key Ab properties for Ab-mediated immunotherapy
11. Antibody structure and classes
12. Affinity and avidity
13. Immunogenicity (1)
14. Immunogenicity (2)
15. Half-life
16. Ab effects on B cell function
17. CD20: function, structure and expression
18. CD20 hypothetical structure on B lymphocytes
19. CD20 complex-mediated Ca2+ conductance
20. Ab binding to CD20 inhibits decrease in [Ca2+]i
21. CD20-deficient B cell [Ca2+]i responses
22. Membrane spanning-4A gene family
23. MS4a expression by mouse tissues
24. Antibody effects on B cell function
25. Antibody dependant cellular cytotoxicity
26. Mouse anti-mouse CD20 monoclonal antibodies
27. MB20 mAb depletion of B cells in vivo
28. CD20 mAb effects on bone marrow B cells
29. CD20 mAb depletes blood B cells
30. CD20 mAb depletes spleen B cells in vivo
31. CD20 mAb eliminates majority of mature B cells
32. B cell depletion after CD20 mAb treatment
33. The peritoneal cavity provides a protective niche
34. Inflammation abrogates the protective niche
35. FcR expression is required for B cell depletion
36. B cell depletion by CD20 requires monocytes
37. CD20 antibodies induce ADCC
38. Complement dependent cytotoxicity (CDC)
39. B cell depletion does not require C'/ T/ NK cells
40. Mouse survival following A20 lymphoma inoculation
41. CD20 treatment eliminates most of mature B cells
42. Non-responsiveness and resistance to CD20 mAb
43. CD20 immunotherapy for autoimmunity
44. S.c CD20 mAb administration is effective
45. B cell depletion in TSK/+ mice by CD20 mAb
46. B cell depletion reduces skin fibrosis
47. CD20-directed immuotherapies
48. Mechanistic studies of CD20 mAb immunotherapy

Topics Covered

• Antibody targeting of B-cell malignancies and autoimmunity
• CD20 antibody immunotherapy
• CD20 structure and function
• Antibody-dependent cellular cytotoxicity
• Complement-dependent cytotoxicity
• Mouse models of CD20 immunotherapy
• Lymphoma immunotherapy
• Immunotherapy for autoimmunity

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. Thomas Tedder has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.